Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ)

Executive Summary

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is a leading Chinese manufacturer of heparin-based active pharmaceutical ingredients (APIs) and finished dosage forms, primarily used as anticoagulants and antithrombotics. Listed on the Shenzhen Stock Exchange (300255.SZ), the company is a key player in the global heparin supply chain, benefiting from China's strong position in heparin raw materials. Its integrated operations from raw material sourcing to finished product manufacturing provide cost advantages and supply chain security. The company focuses on both domestic and international markets, with a diversified product portfolio including unfractionated heparin, low molecular weight heparins, and related derivatives. Given the growing global incidence of thromboembolic disorders and an aging population, demand for heparin products is expected to remain robust, supporting steady revenue growth. However, the company faces risks from regulatory changes in export markets, pricing pressures, and potential competition from synthetic alternatives.

Upcoming Catalysts (preview)

• Q4 2026FDA approval for heparin-based injectable ANDA60% success
• Q2 2027Expansion of heparin API production capacity in Shijiazhuang80% success
• Q1 2027Positive top-line results from Phase III trial of novel LMWH candidate50% success